How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity
Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …